Axogen, Inc. announced an upsized underwritten public offering of 4,000,000 shares of its common stock at $31.00 per share, expected to raise approximately $124 million. The offering is set to close on January 23, 2026. Wells Fargo Securities and Mizuho are the lead book-running managers. Axogen plans to use the proceeds for various purposes, including early payoff of its term loan facility. The offering is being made pursuant to an automatic shelf registration statement. Axogen is a global leader in developing surgical solutions for peripheral nerve function restoration.

For more information, prospective investors can access the preliminary prospectus supplement and accompanying prospectus on the SEC’s website. Axogen focuses on peripheral nerve repair technologies and aims to make nerve repair the standard of care. The company’s product portfolio includes Avance®, Axoguard Nerve Connector®, and more. This press release contains cautionary statements concerning forward-looking statements, urging investors not to rely solely on these forward-looking statements. It is advised to read the prospectus and other filings for complete information.

Read more at GlobeNewswire: Axogen Announces Pricing of Upsized $124 Million Public